Insider · CIK 0001534265
Casdin Partners Master Fund, L.P.
Files at BLFS (BIOLIFE SOLUTIONS INC), LAB (STANDARD BIOTOOLS INC.). First filing Mar 4, 2025, latest Jun 12, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LAB: STANDARD BIOTOOLS INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | BIOLIFE SOLUTIONS INC | $24M 1,000,000 shares | -11% | - | |
| 43Moderate | LABbuy STANDARD BIOTOOLS INC. | $5.1M 4,820,959 shares | +9% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2025 | BLFS BIOLIFE SOLUTIONS INC | SOpen-market sale Common Stock, par value $0.001 per shareindirect: See footnote | -1,000,000 | $23.80 | $24M | 7,707,165 | Jun 12, 2025 |
| Apr 7, 2025 | BLFS BIOLIFE SOLUTIONS INC | JOther Common Stock, par value $.001 per shareindirect: See footnote | +27,994 | - | - | 8,735,159 | Apr 9, 2025 |
| Feb 28, 2025 | LAB STANDARD BIOTOOLS INC. | POpen-market purchase Common Stockindirect: See footnote | +4,820,959 | $1.07 | $5.1M | 58,846,780 | Mar 4, 2025 |
| Feb 28, 2025 | LAB STANDARD BIOTOOLS INC. | JOther Common Stockindirect: See footnote | +545,000 | $1.07 | $580k | 59,391,780 | Mar 4, 2025 |
| Feb 28, 2025 | LAB STANDARD BIOTOOLS INC. | JOther Common Stockindirect: See footnote | -545,000 | $1.07 | $580k | 0 | Mar 4, 2025 |
| Feb 28, 2025 | LAB STANDARD BIOTOOLS INC. | AGrant or award Common Stock | +58,215 | $1.07 | $62k | 2,806,470 | Mar 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.